Chimeric Compounds for Targeted Cytokine Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and autoimmune diseases, such as rheumatoid arthritis and cancer, face challenges with the short half-life of cytokines like IL-2, leading to high dosages and systemic side effects, and the need for targeted therapies to modulate protein levels and restore homeostasis.
Innovation Solution
Development of chimeric compounds comprising a targeting group, a linker group, and binding groups for ubiquitin-mediated proteolysis enzymes (E1, E2, or E3) to specifically modulate protein levels, including those involved in cytokine activity and cell survival, thereby treating diseases associated with cytokines, inflammation, and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If large amounts of IL-2 are injected to achieve therapeutic levels, then therapeutic effect is improved, but systemic side effects worsen
Solution Approach 1:
The patent applies local quality by creating a chimeric compound where the IL-2 cytokine is fused with a targeting group that directs the therapeutic agent specifically to tumor cells. This ensures that the therapeutic effect is concentrated at the tumor site rather than being distributed systemically, thereby improving efficacy while reducing systemic side effects
Solution Approach 2:
The patent uses a targeting group as an intermediary that mediates the delivery of IL-2 to tumor cells. This intermediary component enables specific recognition and binding to tumor cell surfaces, facilitating localized delivery of the cytokine and reducing unnecessary systemic exposure
2Object-affected harmful factors
If protein antagonists are used to reduce pro-inflammatory cytokines, then inflammation is reduced, but treatment complexity increases
Solution Approach 1:
The patent employs composite materials by combining the IL-2 cytokine with a targeting group to create a chimeric compound. This composite structure integrates both the therapeutic function (IL-2 activity) and the targeting function (tumor-specific delivery) into a single molecule, simplifying the treatment approach while maintaining anti-inflammatory and anti-tumor effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively modulate protein levels to restore homeostasis, reducing inflammation and inhibiting cytokine activity, thereby providing a more targeted and tolerable therapeutic approach for inflammatory and autoimmune diseases.
Implementation Method 1
binding groups for ubiquitin-mediated proteolysis enzymes (E1, E2, or E3) to specifically modulate protein levels
Data Source
AI summary
The present invention provides chimeric compounds that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CK1-alpha activity and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as cytokine-mediated diseases, disorders, and conditions, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant rejection, and cancer, are provided.